Angel is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her practice focuses on the preparation and prosecution of patent applications and counseling the clients on freedom-to-operate and patent validity/invalidity analyses.
Prior to joining the firm, Angel was an associate at a Washington, D.C., law firm where she focused on preparing patent applications and responses to office actions, managing patent portfolios, reviewing foreign patent filings, and drafting instructions to foreign associates.
Angel’s technical expertise includes microbiology, molecular biology, biochemistry, and genetics. During her doctoral studies at Clark University, she conducted scientific research on the impact of heavy metal on the antioxidant defenses of bacteria. Her dissertation was titled “The Impact of Mercury on Antioxidant Defenses in Shewanella oneidensis MR-1 and Characterization of Chromosomal mer operons in Xanthobacter autotrophicus Py2.”
Angel is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her practice focuses on the preparation and prosecution of patent applications and counseling the clients on freedom-to-operate and patent validity/invalidity analyses.
Prior to joining the firm, Angel was an associate at a Washington, D.C., law firm where she focused on preparing patent applications and responses to office actions, managing patent portfolios, reviewing foreign patent filings, and drafting instructions to foreign associates.
Angel’s technical expertise includes microbiology, molecular biology, biochemistry, and genetics. During her doctoral studies at Clark University, she conducted scientific research on the impact of heavy metal on the antioxidant defenses of bacteria. Her dissertation was titled “The Impact of Mercury on Antioxidant Defenses in Shewanella oneidensis MR-1 and Characterization of Chromosomal mer operons in Xanthobacter autotrophicus Py2.”
- The George Washington University Law School, 2018
With Honors; Associate, The George Washington Law Review; Member, Student Intellectual Property Law Association
- Ph.D., Biology, Clark University, 2015
- B.S., Biotechnology, Nanjing Agricultural University, 2010
- State Bar of Virginia
- U.S. District Court for the Eastern District of Virginia
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
- The George Washington University Law School, 2018
With Honors; Associate, The George Washington Law Review; Member, Student Intellectual Property Law Association
- Ph.D., Biology, Clark University, 2015
- B.S., Biotechnology, Nanjing Agricultural University, 2010
- State Bar of Virginia
- U.S. District Court for the Eastern District of Virginia
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
Select Publications:
- Co-author, “Gene Therapy Policies Can Strike An Ethical Balance,” Law360, May 3, 2019
- Co-author, “New USPTO Guidance May help Diagnostics Patents,” Law360, April 22, 2019
- Co-author, “Mercury reduction and methyl mercury degradation by the soil bacterium Xanthobacter autotrophicus Py2,” 81(22) Applied and Environmental Microbiology 7833-7838, 2015
- Co-author, “The impact of ionic mercury on antioxidant defenses in two mercury-sensitive anaerobic bacteria,” 26(6) BioMetals 1023-1031, 2013
Select Publications:
- Co-author, “Gene Therapy Policies Can Strike An Ethical Balance,” Law360, May 3, 2019
- Co-author, “New USPTO Guidance May help Diagnostics Patents,” Law360, April 22, 2019
- Co-author, “Mercury reduction and methyl mercury degradation by the soil bacterium Xanthobacter autotrophicus Py2,” 81(22) Applied and Environmental Microbiology 7833-7838, 2015
- Co-author, “The impact of ionic mercury on antioxidant defenses in two mercury-sensitive anaerobic bacteria,” 26(6) BioMetals 1023-1031, 2013
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
- Privacy Policy
- Terms of Use
- Accessibility